SCR7 pyrazine

SKU: orb1307614

Description

SCR7 pyrazine is a small molecule that potently inhibits non-homologous end joining (NHEJ) while promoting homology-directed repair (HDR). It can enhance CRISPR-Cas9-mediated gene editing efficiency up to 19-fold in vitro and is a valuable research tool for precise genome engineering applications.

Research Area

Molecular Biology

Key Properties

• CAS Number: 14892-97-8
• MW: 332.4
• Purity: >98%
• Formula: C₁₈H₁₂N₄OS
• SMILES: O=C1NC(=S)NC2=NC(C3=CC=CC=C3)=C(N=C12)C1=CC=CC=C1
• Target: DNA
• Solubility: Soluble in DMSO (up to 35 mg/ml)

Bioactivity

• In Vivo:
  SCR7 treatment (10 mg/kg, i.m.) signi cantly reduces breast adenocarcinoma-induced tumor, and exhibits 4-fold increase in lifespan compared with control group. However, in Swiss albino mice with Dalton's lymphoma tumor model, SCR7 (20 mg/kg, i.p.) exhibits neither tumor regression nor increase in lifespan. In BALB/c mice, SCR7 (20 mg/kg, i.p.) signi cantly enhances the cytotoxic effects of radiation, etoposide and 3-Aminobenzamide on tumor derived from Dalton's lymphoma (DLA) cells.
• In Vitro:
  SCR7 effectively inhibits the formation of multimers at 200 μM and above. SCR7 successfully inhibits cell proliferation of MCF7, A549, HeLa, T47D, A2780, HT1080, and Nalm6 with IC50 of 40, 34, 44, 8.5, 120, 10, and 50 μM, respectively. SCR7 suppresses the NHEJ repair of CRISPR-Cas9-induced DSBs.
• Cell Research:
  Cell proliferation of cancer cells are determined by MTT and trypan blue assays. Briefly, MCF7, CEM, HeLa, A549, HT1080, A2780, T47D, Nalm6, N114 and K562 cells are grown in presence of SCR7 (10, 50, 100, and 250 μM) for 24 or 48 h, and subjected to MTT or trypan blue assays. Each experiment is repeated a minimum of three independent times. (Only for Reference)

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

SCR7-G; SCR7-X

Compound Identifiers

PubChem CID

10688007